Cullinan Therapeutics, Inc. (CGEM)
9.06
-0.01
(-0.11%)
USD |
NASDAQ |
Nov 20, 11:01
Cullinan Therapeutics Free Cash Flow : -165.47M for Sept. 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2026 | -165.47M |
| June 30, 2026 | -159.26M |
| March 31, 2026 | -178.65M |
| December 31, 2025 | -175.76M |
| September 30, 2025 | -174.27M |
| June 30, 2025 | -171.53M |
| March 31, 2025 | -150.21M |
| December 31, 2024 | -145.30M |
| September 30, 2024 | -126.81M |
| June 30, 2024 | -126.81M |
| March 31, 2024 | -121.57M |
| December 31, 2023 | -134.48M |
| September 30, 2023 | -142.22M |
| Date | Value |
|---|---|
| June 30, 2023 | -162.68M |
| March 31, 2023 | -157.04M |
| December 31, 2022 | -127.80M |
| September 30, 2022 | -117.10M |
| June 30, 2022 | -73.05M |
| March 31, 2022 | -63.83M |
| December 31, 2021 | -43.43M |
| September 30, 2021 | -37.70M |
| June 30, 2021 | -36.22M |
| March 31, 2021 | -26.28M |
| December 31, 2020 | -29.78M |
| September 30, 2020 | -25.22M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Climb Bio, Inc. | -53.64M |
| Oncolytics Biotech, Inc. | -28.39M |
| Sangamo Therapeutics, Inc. | -90.46M |
| Sarepta Therapeutics, Inc. | 167.79M |
| Anixa Biosciences, Inc. | -7.376M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -43.08M |
| Cash from Investing (Quarterly) | 51.64M |
| Cash from Financing (Quarterly) | 1.062M |
| Free Cash Flow Per Share (Quarterly) | -0.6669 |
| Free Cash Flow to Equity (Quarterly) | -43.02M |
| Free Cash Flow to Firm (Quarterly) | -43.08M |
| Free Cash Flow Yield | -28.07% |